HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Frankfurt court will hold hearing June 26 to assess case brought by hedge fund group Elliott Associates, a minority shareholder of Wella that is seeking to bring down Procter & Gamble's bid for the German company, a law firm for Elliott says. A ruling in favor of Elliott would find P&G's bid is prohibited according to German law, in which case "any and all contracts or legal acts carried out would be nullified," firm maintains. Directed to German regulatory authorities, Elliott's lawsuit maintains P&G's offering for Wella shares is too low. The group failed to get a preliminary injunction against P&G's bid last month. P&G's second tender period for accepting Wella shares ended June 20 (1"The Rose Sheet" June 2, 2003, p. 8)...

You may also be interested in...

Wella Integration To Proceed Regardless Of Offer Outcome, P&G Says

Procter & Gamble remains confident it will acquire outstanding shares of Wella during an additional two-week acceptance period beginning June 6, the company stated May 29, the day after its initial tender offer for the German hair care company closed

Virtual Adcom Vet Says In-Person Events May Be Better For Product Approval Recommendations

Syndax CEO also says US FDA’s virtual meetings would benefit from having advisory committee members on camera, which may be a technology challenge.

US FDA Eyes Ocular Risks With GlaxoSmithKline’s Myeloma Drug Belantamab

Heading into an advisory committee review, agency suggests belantamab’s risks of keratopathy and other ocular issues have not been fully characterized and questions whether the proposed mitigation measures, including dosing modifications, are adequate.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts